Helen S. Kim
Ms. Kim joined as a director in 2018 and has over 25 years' experience in leadership roles in biotechnology, most recently as Executive Vice President of Business Development at Kite Pharma. She led the acquisition of Kite Pharma by Gilead in September 2017. Ms. Kim served as Strategic Advisor of NGM Biopharmaceuticals from January 2012 through January 2014. Ms. Kim served as the Chief Business Officer at NGM Biopharmaceuticals from August 2009 to January 2012. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences, where she restructured and repositioned the company prior to successfully negotiating its sale to Bristol-Myers Squibb in 2008. Ms. Kim's additional industry experience includes executive positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Ms. Kim recently served as Chief Program Officer for the Gordon and Betty Moore Foundation. Currently, she serves as a director for Exicure, a public company, and private companies Peloton Therapeutics and Applied Molecular Transport. Ms. Kim received a BS in Chemical and Biomedical Engineering from Northwestern University and a MBA from the University of Chicago.